This article appears to raise concerns about challenges within the supply chain - something the industry is keenly aware of as it continues to plug the gaps created by those pharmacists who choose to put profits above the very real needs of patients.
Whilst parallel trade is legal we have an ethical and moral obligation to make sure those medicines in the UK supply chain reach UK patients; however, current challenges cannot be solved by any part of the supply chain in isolation and will only be addressed by all healthcare partners working collaboratively to find an appropriate solution.
Steps have already been taken to improve supply chain issues with best practice guidance launched by the Department of Health earlier this year and signed up to by manufacturers, wholesalers and pharmacists. This has not yet been sufficient to drive improvement and the ABPI is looking to go further, and bring together those involved across the supply chain to work collaboratively to look at additional steps we can take to ensure that people get the right medicines when they need them.
We hope our suggestion to find a solution that benefits UK patients will be welcomed by our partners across the board.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
About the ABPI
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.